Oncolytic Virus Therapy Global Market Report 2025

Oncolytic virus therapy, also referred to as virotherapy, represents a cancer treatment approach employing viruses to selectively target and eliminate cancer cells within the body. The primary goal of this therapy is to leverage modified or naturally occurring viruses capable of infecting and replicating specifically within cancerous cells while preserving healthy cells.

The key categories of oncolytic virus therapy include HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), among others. HSV-based oncolytic virus therapy employs the herpes simplex virus (HSV) as the foundational component for treatment. Various virus types encompass genetically modified oncolytic viruses as well as oncolytic wild-type viruses. These therapies find application across different cancer types such as breast cancer, lung cancer, prostate cancer, melanoma, brain tumors, and blood cancer. They are utilized by healthcare institutions including hospitals, specialized clinics, and cancer research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The oncolytic virus therapy market research report is one of a series of new reports from The Business Research Company that provides oncolytic virus therapy market statistics, including oncolytic virus therapy industry global market size, regional shares, competitors with an oncolytic virus therapy market share, detailed oncolytic virus therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oncolytic virus therapy industry. This oncolytic virus therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncolytic virus therapy market size has grown exponentially in recent years. It will grow from $0.19 billion in 2024 to $0.23 billion in 2025 at a compound annual growth rate (CAGR) of 25.0%. The growth in the historic period can be attributed to improved genetic engineering techniques, increased understanding of tumor microenvironment, clinical successes and regulatory approvals, the rise of immunotherapy in cancer treatment, and advancements in gene delivery systems.

The oncolytic virus therapy market size is expected to see exponential growth in the next few years. It will grow to $0.55 billion in 2029 at a compound annual growth rate (CAGR) of 23.7%. The growth in the forecast period can be attributed to the expansion of oncolytic virus platforms, combination therapies with immune checkpoint inhibitors, personalized medicine approaches, expansion of the clinical trial landscape, regulatory support and guidelines. Major trends in the forecast period include technological advances in delivery systems, advancements in synthetic biology, collaborations and partnerships in the biopharmaceutical industry, advancements in virology and immunology, focus on pediatric oncology.

The forecast of 23.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of genetically modified oncolytic viruses sourced from Germany and Canada, thereby delaying experimental cancer treatments and elevating oncology research expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The escalating prevalence of cancer cases stands poised to drive the growth of the oncolytic virus therapy market. Cancer, a collective term for diseases characterized by uncontrolled cell growth, is a significant global health concern. Oncolytic virus therapy emerges as a promising approach, capable of selectively targeting and eliminating cancer cells while simultaneously triggering an immune response against tumors, providing a dual mechanism for effective cancer treatment. Notably, in January 2023, the American Cancer Society Inc. projected 609,820 cancer deaths and 1,958,310 new cancer cases in the United States for 2022. This stark reality underscores the urgent need for innovative therapeutic approaches, such as oncolytic virus therapy, to address the growing prevalence of cancer cases.

The oncolytic virus therapy market is expected to experience growth propelled by the increasing number of ongoing clinical trials. Clinical trials, essential research studies involving human participants, serve to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. The surge in clinical trials utilizing oncolytic virus therapy underscores the therapeutic potential of this approach, given its ability to selectively target cancer cells while sparing healthy tissue. As of October 2023, ClinicalTrials.gov reported a significant increase in registered studies, rising from 437,523 in 2022 to 468,457 across all 50 states of the United States and 221 countries. Notably, 143,613 studies (31% of the total) are registered in the U.S., with 251,159 studies (54% of the total) registered in non-U.S. locations. This proliferation of clinical trials signifies the growing interest and investment in oncolytic virus therapy as a promising avenue for cancer treatment, contributing to the market's expansion.

Major companies in the oncolytic virus therapy market are focused on securing regulatory approvals to accelerate the launch of innovative cancer treatments. Regulatory approvals refer to the procedure through which health authorities assess and authorize medical products, including drugs, biologics, and medical devices, for market use. For example, in March 2024, ImmVira, a biotechnology firm based in China, received Fast Track designation from the FDA for its oncolytic virus therapy, MVR-T3011 IT. This therapy is intended for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have experienced disease progression after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. The Fast Track designation aims to expedite the development and review process for therapies that address serious conditions with unmet medical needs.

Strategic partnerships play a pivotal role in advancing comprehensive cancer treatments within the oncolytic virus therapy industry. RenovoRx Inc., a US-based clinical-stage biopharmaceutical company, and Imugene Ltd., an Australia-based clinical-stage immuno-oncology company, forged a strategic research collaboration in July 2023. The aim of this partnership is to optimize the delivery of Imugene's oncolytic virus therapy leveraging RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform. Additionally, the collaboration seeks to explore the administration of Imugene's CF33 oncolytic virus technology using RenovoRx's TAMP therapy platform, with a specific focus on treating challenging-to-access tumors. This strategic alliance exemplifies the industry's commitment to collaborative efforts, driving advancements in oncolytic virus therapy for enhanced cancer treatment outcomes.

In April 2022, Recipharm AB, a pharmaceutical company based in Sweden, completed the acquisition of Vibalogics for an undisclosed sum. This strategic move enabled Recipharm AB to enhance its global presence significantly by integrating a comprehensive end-to-end portfolio encompassing development capabilities, GMP drug substance and drug product manufacturing, sterile fill & finish services, as well as analytical and quality control testing. Vibalogics, a German biotechnology firm and a Contract Development and Manufacturing Organization (CDMO), specializes in manufacturing oncolytic viruses, viral vaccines, and gene therapies.

Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

North America was the largest region in the oncolytic virus therapy market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the oncolytic virus therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncolytic virus therapy market includes revenues earned by entities by providing seneca valley virus (SVV), semliki forest virus (SFV), vesicular stomatitis virus (VSV), and sindbis virus (SBV). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncolytic Virus Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncolytic virus therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncolytic virus therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncolytic virus therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: HSV-Based Oncolytic Virus Therapy; Adenovirus-Based Oncolytic Virus Therapy; Reovirus; Poxviruses; NDV (Newcastle Disease Virus); Other Therapy Types
• 2) By Virus Type: Genetically Engineered Oncolytic Viruses; Oncolytic Wild-Type Viruses
• 3) By Application: Breast Cancer; Lung Cancer; Prostate Cancer; Melanoma; Brain Tumor; Blood Cancer
• 4) By End-User: Hospitals; Specialty Clinics; Cancer Research Institutes
• Subsegments:
• 1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC); Other HSV-Based Therapies
• 2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015; AdV-5/3-D24; Other Adenovirus-Based Therapies
• 3) By Reovirus: Reolysin; Other Reovirus Therapies
• 4) By Poxviruses: JX-594 (OncoVac); Other Poxvirus Therapies
• 5) By NDV (Newcastle Disease Virus): NDV-Based Therapies; Other NDV Applications
• 6) By Other Therapy Types: Combination Therapies; Other Emerging Oncolytic Virus Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Sorrento Therapeutics Inc.; AbbVie Inc.; AstraZeneca plc; Amgen Inc.; Boehringer Ingelheim Group; Regeneron Pharmaceuticals; Daiichi Sankyo Company Limited; Kissei Pharmaceutical Co. Ltd.; Takara Bio Inc.; Oncorus Inc.; Replimune Inc.; Vyriad Inc.; Genelux Corporation; Oncolys BioPharma Inc.; Adze Biotechnology; Oncolytics Biotech Inc.; TILT Biotherapeutics Ltd.; Transgene SA; Circio Holding ASA; Lokon Pharma AB; Provectus Biopharmaceuticals Inc.; Vibalogics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.